Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned
Chief Medical Officer of Elicio Therapeutics, Christopher Haqq, M.D., Ph.D., added, “We believe this study represents a critical step forward in KRAS-targeted immunotherapy. By evaluating ELI-002 in combination with mFOLFIRINOX and exploring the additional role of anti-PD-1 blockade, we aim to establish a treatment paradigm that maximizes immune activation while maintaining safety. Our hope is that this approach will deliver meaningful improvements in relapse-free survival and overall survival for patients facing resectable and borderline resectable PDAC in the neo-adjuvant setting. If Phase 1 results are supportive, expanding to a broader population in this setting could enable more PDAC patients to benefit from ELI-002 7P, and also enhance the commercial opportunity for Elicio.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the